Inebilizumab

Uplizna 100 MG Concentrado Para Solucion Para Perfusion

10 mg/ml concentrado para solución para perfusiónSpainMarketedAuthorised 22 Jul 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

UpliznaEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Inebilizumab

Uplizna 100 MG Concentrado Para Solucion Para Perfusion

10 mg/ml concentrado para solución para perfusiónSpainMarketedAuthorised 22 Jul 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

UpliznaEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Uplizna 10 mg/ml, concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Amgen Europe B.V.

UpliznaUnited States · 100MG/10ML · injectable · Viela Bio

Packs

Pack	Code	Status
UPLIZNA 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSION, 3 viales de 10 ml	758062

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Inebilizumab
Strength: 10 mg/ml
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 22 Jul 2022
Registration: 1211602001
Marketing authorisation holder: Amgen Europe B.V.
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/21/1602